Matsumoto Yushi-Seiyaku Co., Ltd.
Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary
Net sales of 11,135 million yen (YoY +6.1%), operating income of 2,270 million yen (YoY +12.1%), net income attributable to owners of parent of 2,004 million yen. Segments include Japan and Asia, and due to resource reallocation and demand recovery, results are solid.
Key Figures
- Net sales: 11,135 million yen (YoY +6.1%)
- Operating income: 2,270 million yen (YoY +12.1%)
- Net income attributable to owners of parent: 2,004 million yen (YoY +31.5%)
AI要約
Section Heading
This Financial Summary outlines the consolidated results and financial position for the first quarter of the fiscal year ending March 2027. Demand is recovering mainly in Japan and Asia, and while considering raw material and energy costs, sales and profits are above the previous year's first quarter. Segment results show notable contributions from Japan and Asia, with SG&A management and exchange rate effects being addressed.
Section 2 Heading
The financial position shows total assets increasing; liabilities have risen partly due to current liabilities, but equity and the equity ratio continue to improve. Cash flow notes are not prepared for this quarter, but the breakdown of depreciation and investment activities is disclosed. Future earnings guidance is based on published materials.
Matsumoto Abies Co., Ltd.
Company overview · Stock price · Financial data · All IR
